Promising drug combo targets Hard-to-Treat salivary cancer
NCT ID NCT05694819
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to see if the tumors shrink and if the treatment is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darolutamide (and goserelin in one group)
What this could lead to
If successful, this could offer a new targeted treatment option for a rare salivary gland cancer that is hard to treat.
What could go wrong
This is a small, early-phase trial with only 57 participants. The drug may not shrink tumors enough, and side effects like fatigue or hormone-related issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba University Hospital
Chiba, Chiba, 260-8677, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
-
Nagoya University Hospital
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, 810-8563, Japan
-
Osaka International Cancer Institute
Osaka, Osaka, 541-8567, Japan
-
The Jikei University Hospital
Tokyo, Tokyo, 105-0003, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
-
Tokyo Medical And Dental University Hospital
Tokyo, Tokyo, 113-8519, Japan
-
Tokyo Medical University Hospital
Tokyo, Tokyo, 160-0023, Japan
-
Yokohama City University Hospital
Yokohama, Kanagawa, 236-0004, Japan